To analyze the efficacy of anti-PD-1 and anti-CTLA4 treatments in different cancer subtypes, we extracted data on immunotherapy in melanoma patients as a reference, and 47 immunotherapy patients were included in the analysis. The gene discussed is CTLA4; the disease is melanoma.